FDA Approved: JENTADUETO — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)

View source ↗

Summary

FDA approved a supplemental application for JENTADUETO, the fixed-dose combination of linagliptin and metformin hydrochloride, submitted by Boehringer Ingelheim…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Jentadueto (linagliptin/metformin)

Snippet

SUPPL AP for JENTADUETO (LINAGLIPTIN AND METFORMIN HYDROCHLORIDE)